As the Republic of Korea strengthens its role in global health, new opportunities are emerging to align with public and private stakeholders in supporting cancer care in low- and middle-income countries (LMICs). This webinar—hosted by City Cancer Challenge (C/Can) in partnership with the Institute for Development and Human Security (IDHS) and the Global Health Research Center at Ewha Womans University—aims to spark dialogue and explore concrete pathways for collaboration.

Why Korea?
Several key trends highlight Korea’s potential to drive impact in global cancer care:

• Strong ODA Performance: Korea is the 14th largest donor in the OECD Development Assistance Committee, allocating US$343.7 million to health and population sectors in 2023.

• Strategic Geographic Overlap: Korea’s priority ODA regions significantly intersect with countries where C/Can is active, particularly in Asia, Oceania, and coastal Africa.

• Growing Pharmaceutical Innovation: Korea’s pharmaceutical sector has seen a 6.7% CAGR (2018–2022), with over 1,650 new drugs in development in 2023—35% focused on cancer.

• Leadership in Oncology Research: In 2023, Korea conducted 783 clinical trials, with over 30% in oncology.